CIBBIM - Nanomedicine
CIBBIM-Nanomedicine. Immune Regulation & Immunotherapy
Dr. Joan Sayós Ortega
Team Dr Hugo Peluffo, Nuria GarciaAndrea Arcas, Andrea Arcas
Summary
During 2015 our Group has been working in the conclusion of diverse projects related with the paper of the CD300 molecules in brain damage and demyelinating diseases. Some of the data generated has been already published during 2015 and we are working in two more manuscripts that we expect to submit in the next months. Moreover, we are finishing another project to characterize the nature of CD300f physiological ligand. Our data demonstrate that CD300f binds to different phospho and esphingolipids only in the presence of a presenting protein. We have identified that protein, opening the way to target this molecule to activate specific myeloid cells as a therapeutic approach to diverse pathologies. Finally, in this year our Group has engaged in new research projects, focusing its interest in diverse aspects of the Immune response, including tumor immunology and the role of innate immune system in diabetes and metabolic disorders.